. "4 Identifying and Understanding Adverse Medical Device Events." Safe Medical Devices for Children. Washington, DC: The National Academies Press, 2005.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Safe Medical Devices for Children
TABLE 4.2 FDA Adverse Event Reports Involving Individuals Under Age 21 (1999–2004)a
1999
2000
2001
2002
2003
2004
TOTAL
Manufacturer
Death
29
39
94
101
96
92
451
Injury
513
483
838
948
1,040
1,371
5,193
Malfunction
523
540
795
1,279
980
438
4,555
Other
185
162
195
147
173
190
1,052
SUBTOTAL
1,250
1,224
1,922
2,475
2,289
2,091
11,251
User Facility
Death
17
10
23
19
14
12
95
Injury
134
131
172
107
76
78
698
Malfunction
69
41
61
48
70
64
353
Other
28
17
22
32
39
32
170
SUBTOTAL
248
199
278
206
199
186
1,316
Importer
Death
0
1
1
0
0
0
2
Injury
7
1
10
43
53
24
138
Malfunction
11
3
13
73
115
42
257
Other
4
19
6
8
2
0
39
SUBTOTAL
22
24
30
124
170
66
436
Voluntary
Death
7
9
9
15
12
15
67
Injury
86
86
111
141
115
144
683
Malfunction
84
70
133
135
138
156
716
Other
25
31
27
35
38
26
182
SUBTOTAL
202
196
280
326
303
341
1,648
GRAND TOTAL
1,722
1,643
2,510
3,131
2,961
2,684
14,651
aNot all reports include information on patient age.
SOURCE: Division of Surveillance Systems, CDRH.
about the device (e.g., brand and model number and even manufacturer) may not have been documented. A later section of this chapter returns to these and other limitations of adverse event reporting programs.
When FDA receives an adverse event or device malfunction report from a manufacturer or other party, it (actually a contractor) checks the report, codes certain information if it has not been coded already by the reporter, and enters the report into the database.2 FDA has developed codes for both clinical outcomes (e.g., cerebral hemorrhage) and device outcomes (e.g.,
2
The description of the event review process and the discussion of analysis priorities are based on an April 15, 2004, presentation to the committee by Thomas P. Gross, M.D., Director, Division of Postmarket Surveillance, Office of Surveillance and Biometrics, CDRH, and a June 24, 2004, presentation by Rosalie Bright, Epidemiologist, Division of Postmarket Surveillance, Office of Surveillance and Biometrics, CDRH (see, Gross 2004; Bright, 2004).